Regeneron jumps on analyst note, Viehbacher comments

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) added $16.37 to $289.97 on Friday on a note from RBC Capital highlighting Regeneron and the biotech's alirocumab ( REGN727), which is in the Phase III ODYSSEY MONO trial to treat hypercholesterolemia. Analyst Adnan Butt raised his price target to $293 from $286 based on increasing the value for alirocumab to $28 per share from $21. Data from the trial are expected by year end. Alirocumab is a human mAb targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). ...